83 related articles for article (PubMed ID: 12682647)
1. Reduced expression of H19 in bone marrow cells from chronic myeloproliferative disorders.
Bock O; Schlué J; Kreipe H
Leukemia; 2003 Apr; 17(4):815-6. PubMed ID: 12682647
[No Abstract] [Full Text] [Related]
2. Down-regulation of the IGF-2/H19 locus during normal and malignant hematopoiesis is independent of the imprinting pattern.
Tessema M; Länger F; Bock O; Seltsam A; Metzig K; Hasemeier B; Kreipe H; Lehmann U
Int J Oncol; 2005 Feb; 26(2):499-507. PubMed ID: 15645136
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloproliferative disorders--introduction.
Skoda R; Prchal JT
Semin Hematol; 2005 Oct; 42(4):181-3. PubMed ID: 16210031
[No Abstract] [Full Text] [Related]
4. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
[TBL] [Abstract][Full Text] [Related]
5. Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
Nakata Y
Hiroshima J Med Sci; 1993 Jun; 42(2):67-71. PubMed ID: 8253600
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
7. Lhx2 expression in hematopoietic progenitor/stem cells in vivo causes a chronic myeloproliferative disorder and altered globin expression.
Richter K; Pinto do O P; Hägglund AC; Wahlin A; Carlsson L
Haematologica; 2003 Dec; 88(12):1336-47. PubMed ID: 14687986
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
9. Expression of cell cycle regulatory genes in chronic myelogenous leukemia.
Iolascon A; Della Ragione F; Giordani L; Serra A; Saglio G; Faienza MF
Haematologica; 1998 Sep; 83(9):771-7. PubMed ID: 9825572
[TBL] [Abstract][Full Text] [Related]
10. Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia.
Ruan GR; Qin YZ; Chen SS; Li JL; Ma X; Chang Y; Wang YZ; Fu JY; Liu YR
Leuk Res; 2006 Sep; 30(9):1159-65. PubMed ID: 16507320
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of chronic myeloproliferative syndromes using the technics of in vitro hematopoiesis (the origin and function of marrow stromal cells in CML)].
Takahashi M; Fujiwara M
Rinsho Ketsueki; 1988 Jul; 29(7):994-1000. PubMed ID: 3184486
[No Abstract] [Full Text] [Related]
12. Activation of Ha-ras in human chronic granulocytic and chronic myelomonocytic leukaemia.
Gow J; Hughes D; Farr C; Hamblin T; Oscier D; Brown R; Padua RA
Leuk Res; 1988; 12(10):805-10. PubMed ID: 3059070
[TBL] [Abstract][Full Text] [Related]
13. Chronic myelogenous leukemia molecular signature.
Nowicki MO; Pawlowski P; Fischer T; Hess G; Pawlowski T; Skorski T
Oncogene; 2003 Jun; 22(25):3952-63. PubMed ID: 12813469
[TBL] [Abstract][Full Text] [Related]
14. [The aberrant imprinting of insulin-like growth factor II and H19 in human hepatocellular carcinoma].
Wu J; Qin Y; Li B; He WZ; Sun ZL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jan; 38(1):49-52. PubMed ID: 17294726
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of insulin-like growth factor-2 (IGF-2) in Philadelphia chromosome negative chronic myeloproliferative disorders.
Bock O; Tessema M; Serinsöz E; von Wasielewski R; Büsche G; Kreipe H
Leuk Res; 2004 Nov; 28(11):1145-51. PubMed ID: 15380337
[TBL] [Abstract][Full Text] [Related]
16. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis.
Barsyte-Lovejoy D; Lau SK; Boutros PC; Khosravi F; Jurisica I; Andrulis IL; Tsao MS; Penn LZ
Cancer Res; 2006 May; 66(10):5330-7. PubMed ID: 16707459
[TBL] [Abstract][Full Text] [Related]
17. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.
Hussein K; Bock O; Theophile K; Seegers A; Arps H; Basten O; Grips KH; Franz-Werner J; Büsche G; Kreipe H
Leukemia; 2008 May; 22(5):1059-62. PubMed ID: 17972958
[No Abstract] [Full Text] [Related]
18. IGF2 but not H19 shows loss of imprinting in human glioma.
Uyeno S; Aoki Y; Nata M; Sagisaka K; Kayama T; Yoshimoto T; Ono T
Cancer Res; 1996 Dec; 56(23):5356-9. PubMed ID: 8968084
[TBL] [Abstract][Full Text] [Related]
19. [Detection of bcr/abl gene expression on bone marrow cell colonies in chronic myelogenous leukemia by reverse transcriptase-polymerase chain reaction].
Luo Z; Chen H; Luo S; Tang L; Wang J
Hunan Yi Ke Da Xue Xue Bao; 1999; 24(5):418-20. PubMed ID: 12080671
[TBL] [Abstract][Full Text] [Related]
20. The 3' portion of the mouse H19 Imprinting-Control Region is required for proper tissue-specific expression of the Igf2 gene.
Hagège H; Nasser R; Weber M; Milligan L; Aptel N; Jacquet C; Drewell RA; Dandolo L; Surani MA; Cathala G; Forné T
Cytogenet Genome Res; 2006; 113(1-4):230-7. PubMed ID: 16575185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
